TinyGemsBreaks Archive - Page 101 of 128

WednesdayOct 26, 2022 12:41 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which will evaluate the effectiveness of CycloSam in treating patients with bone cancer. According to the announcement, RCINJ is part of Rutgers Health and is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, a designation granted to institutions based on scientific leadership, resources and track record of…

WednesdayOct 26, 2022 12:05 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Official Start of the Demonstrator US Tour for Its FIVE EV Crossover

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced the beginning of the Mullen FIVE Strikingly Different EV Crossover Tour, which will commence on Oct. 27 in Pasadena, California. Due to overwhelming interest, the tour has been expanded to add new dates of Nov. 1 and 2 at Angel Stadium in Anaheim, California. “When we announced the Pasadena location, we received an overwhelmingly positive response and were completely booked out in a matter of hours. So, we decided to add an additional LA area stop to ensure more people have the opportunity to experience the FIVE,” said…

WednesdayOct 26, 2022 11:18 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is Oct. 25-31, 2022. “In severe cases of epidermolysis bullosa, or EB, the very fragile skin tears easily and forms painful blisters and open wounds that do not heal quickly,” said Alexandra Mancini, SVP of Clinical and Regulatory Affairs for InMed. “EB is a very important but rare disease that does not get the attention it deserves. EB Awareness…

TuesdayOct 25, 2022 12:45 pm

TinyGemsBreaks – Freight Technologies Inc.’s (NASDAQ: FRGT) Solutions Designed to Improve Customers’ Efficiency, Profitability, Logistic Experiences

Freight Technologies (NASDAQ: FRGT), a company that develops solutions aimed at optimizing and automating the supply chain process, aims to revolutionize logistics operations for brokers, carriers and shippers by leveraging technology infrastructure to improve experiences and efficiency. “The infrastructure combines everything in a single control center, optimizing logistics, making fleets more efficient and reducing transportation costs,” reads a recent article. “Through its wholly owned subsidiary Freight App Inc. (‘Fr8App”), the company offers solutions such as the Fr8App Platform, a B2B cross-border shipping marketplace powered by artificial intelligence and machine learning; Fr8FMS, a solution that enables transportation companies and owners to…

TuesdayOct 25, 2022 10:41 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Webcast to Discuss M&A, International Markets

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has scheduled an analyst call for Oct. 26, 2022, at 2 p.m. EST. According to the announcement, the call will focus on the company’s recent M&A activity as well as growth opportunities in the international space. Leadership from Flora Growth, along with Franchise Global Health Inc., will be on the call to discuss the recent definitive agreement that two companies have signed regarding acquisition; discussion will also center on global opportunities within the cannabis industry. Through its subsidiaries, Franchise Global Health is a multinational…

MondayOct 24, 2022 10:56 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces the I-GO(TM), a Fully EU Homologated Vehicle

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has secured exclusive sales, distribution and branding rights to the new compact urban delivery electric vehicle, the I-GO, which is fully EU Standard homologated and certified for sale in select European markets. The I-GO bridges the gap between the growing demand for quick deliveries and space constraints found throughout the dense cities of Europe. “Securing the exclusive sales, distribution and branding rights in major European countries for a ready to market electric commercial delivery vehicle is a huge win for the company. The company plans on…

MondayOct 24, 2022 10:25 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters into Acquisition Agreement with German-Based Pharmaceutical, Medical Cannabis Distributor

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has inked a definitive agreement with Franchise Global Health Inc. (TSX.V: FGH), a multinational operator in the medical cannabis and pharmaceutical industry. The agreement outlines Flora Growth’s plans to acquire 100% of Franchise Global Health, which has principal operations in Germany, in an all-stock transaction. According to the agreement, the acquisition gives FLGC a foothold in German’s medical cannabis space because FGH’s German businesses service an estimated 1,200 pharmacies in the country; FGH also provides noncannabis medical products to 28 additional countries. In the first…

FridayOct 21, 2022 3:17 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake,” reads a recent article. “Lexaria’s vision…

FridayOct 21, 2022 2:54 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Continually Upgrading Systems, Gaming Content to Maintain Competitive Edge

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, is leveraging the growth opportunity that has arisen as casino operators embrace digital avenues. “Golden Matrix’s GM-AG System is the industry standard for gaming platforms, including leading graphics and over 10,000 games to give casino operators a copious number of options and management software to keep customers happy and loyal to their brand. As a rule, casinos can’t have enough online table games, which is right in GMGI’s wheelhouse… Golden Matrix is only scratching the surface of the bounds of its potential domain. Most…

FridayOct 21, 2022 11:53 am

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023. Pending regulatory approvals, the trials will be performed in autoimmune diseases, first studying psoriasis. Dr. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of multinational pharmaceutical company Schering AG’s therapeutics business unit, is leading Adimune’s(TM) ADI(TM) immune modulation…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks